CARMIEL, Israel--(BUSINESS WIRE)--Protalix BioTherapeutics, Inc. (Amex: PLX), announced today enrollment of the first patient in a worldwide, multi-center, open-label, switchover trial to assess the safety and efficacy of prGCD. prGCD is the Company’s proprietary plant cell expressed recombinant form of human glucocerebrosidase (GCD) that is in development for the treatment of Gaucher disease, a rare and serious lysosomal storage disorder in humans. The trial is designed to include 15 patients with Gaucher disease that are currently undergoing enzyme replacement therapy with imiglucerase (Cerezyme®).
